Yuhan Collaborates with GI Innovation for its Allergy Treatment Worth up to $1.2B
Shots:
- GI Innovations to receive $17M upfront- $1.2B as development & commercialization milestones along with royalties on sales of therapy
- Yuhan to get global rights (Ex-Japan) to develop and commercialize GI-301 while collaborates with GI Innovations for the development of therapy
- As per collaboration- the companies will develop allergy treatment across all four major allergic diseases-allergic asthma- chronic urticaria- atopic dermatitis- and food allergy
Click here to read full press release/ article | Ref: GI Innovations | Image: LinkedIn
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
